BioXcel Therapeutics Inc represents a strong commitment to innovation and patient-centric approaches in the field of biopharmaceuticals. The company values scientific excellence, integrity, and ethical conduct in its pursuit of developing novel therapies. With a focus on leveraging artificial intelligence (AI) and big data analytics, BioXcel Therapeutics aims to revolutionize drug discovery and improve patient outcomes. The company actively collaborates with leading institutions to advance research and development efforts. Through its dedication to transformative science and a patient-focused corporate philosophy, BioXcel Therapeutics Inc strives to bring innovative treatments to market and make a positive impact on global healthcare.

BioXcel Therapeutics Inc is primarily present in the United States.

BioXcel Therapeutics Inc has achieved several significant milestones. The company successfully completed a Phase 1b clinical trial for its lead product candidate, BXCL501, in patients with schizophrenia and bipolar disorder. In addition, BioXcel Therapeutics received Fast Track designation from the U.S. Food and Drug Administration for the development of BXCL501. The company also progressed the clinical development of BXCL701, an immuno-oncology therapy, by initiating Phase 1b/2 clinical trials in prostate cancer and pancreatic cancer. Furthermore, BioXcel Therapeutics has formed collaborations and partnerships with renowned academic institutions and pharmaceutical companies to explore the full potential of its innovative therapies.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines using artificial intelligence. Founded in 2017, the company utilizes its proprietary innovation platform to engineer drugs targeting unmet medical needs. BioXcel Therapeutics combines data-driven insights with traditional drug development techniques to effectively identify and advance innovative therapies. With a strategic focus on neurological and immuno-oncology disorders, BioXcel Therapeutics aims to improve patient outcomes through its robust pipeline of product candidates. The company has established collaborations with renowned institutions and continues to push the boundaries of drug discovery and development through its cutting-edge approach.

The main competitors of BioXcel Therapeutics Inc in the market include Genentech, Roche, Novartis, and Pfizer.

BioXcel Therapeutics Inc is primarily active in the healthcare and biotechnology industries.

BioXcel Therapeutics Inc is a biopharmaceutical company that focuses on developing transformative medicines using artificial intelligence (AI) and data analytics. The company's business model revolves around identifying innovative drug candidates and advancing them through preclinical and clinical trials. By leveraging AI algorithms, BioXcel Therapeutics aims to rapidly discover and develop therapies for unmet medical needs. Through strategic collaborations and partnerships, the company aims to commercialize these novel treatments. With its unique approach combining AI technology and pharmaceutical expertise, BioXcel Therapeutics Inc strives to revolutionize the way drugs are discovered and developed, ultimately improving patient outcomes.

BioXcel Therapeutics에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

BioXcel Therapeutics에 대한 현재 KUV는 계산할 수 없습니다.

BioXcel Therapeutics에 대한 AlleAktien 품질 점수는 4/10입니다.

BioXcel Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

BioXcel Therapeutics의 현재 이익을 계산할 수 없습니다.

BioXcel Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of novel therapies for severe diseases. The company utilizes an innovative data science-based approach to identify drug candidates and rapidly develop precision medicine. The company has developed its technology platform BXCL501, which is based on pharmacological sedation and analgesia technology. This is a unique method for rapidly developing effective and precise medications that target specific biological target molecules. Another important aspect of the company is the BXCL701 platform, which focuses on immuno-oncology. BioXcel Therapeutics utilizes its specialized technologies to identify and develop drug candidates for various stages of severe diseases. This includes CNS disorders, psychoactive disorders, immuno-oncology, neurodegenerative diseases, and other rare diseases. The company also offers a wide range of medications, including BXCL501 (Dexmedetomidine), BXCL701, BXCL702, and BXCL501 (Methylphenidate). The BXCL501 platform aims to prevent and treat psychoactive disorders and anxiety, while BXCL701 focuses on preventing and stopping tumors in the human body. BioXcel Therapeutics has built a pipeline of multiple international investigational products and development programs focusing on groundbreaking therapies. This is aimed at meeting the demands of patients in the coming years. With the enormous potential of innovative therapies, the company is focused on expansion to further diversify its focus and expand its offering of therapeutic solutions. Conclusion: BioXcel Therapeutics Inc is a company that plays a leading role in the discovery and development of innovative therapeutics. By using data science technologies and focusing on precision medicine approaches, the company efficiently identifies drug candidates targeting biological target molecules to treat severe diseases. Through its BXCL501 and BXCL701 platforms, it offers a broad range of medications to further strengthen its leadership position in the therapeutics field. With a solid portfolio of development programs and international investigational products, the company is focused on expansion and continues to prioritize the development of promising new therapies to meet the needs of patients.

BioXcel Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

BioXcel Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

BioXcel Therapeutics의 ISIN은 US09075P1057입니다.

BioXcel Therapeutics의 WKN은 A2JF20입니다.

BioXcel Therapeutics의 티커는 BTAI입니다.

지난 12개월 동안 BioXcel Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 BioXcel Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

BioXcel Therapeutics의 현재 배당 수익률은 입니다.

BioXcel Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

BioXcel Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

BioXcel Therapeutics은 '건강' 섹터에 속합니다.

BioXcel Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 BioXcel Therapeutics는 0 USD를 배당금으로 지급했습니다.

BioXcel Therapeutics의 배당금은 USD에 지급됩니다.